{"id":1700,"date":"2021-01-28T13:33:44","date_gmt":"2021-01-28T13:33:44","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/apsard-and-tris-pharma-announce-the-2021-tris-research-award-in-adhd\/"},"modified":"2024-06-03T11:07:44","modified_gmt":"2024-06-03T10:07:44","slug":"apsard-and-tris-pharma-announce-the-2021-tris-research-award-in-adhd","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/apsard-and-tris-pharma-announce-the-2021-tris-research-award-in-adhd\/","title":{"rendered":"APSARD and Tris Pharma Announce the 2021 Tris Research Award in ADHD"},"content":{"rendered":"\r\n

MONMOUTH JUNCTION, NJ, January 28, 2021 \/ PRNewswire\/ – The American Professional Society of ADHD and Related Disorders (\u201cAPSARD\u201d), a professional organization focused on improving outcomes for individuals with ADHD and their families, and Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder, have jointly announced the 2021 recipients of a multi-year research award to advance and recognize outstanding research in the field of ADHD. <\/p>\r\n\r\n\r\n\r\n

The Tris Research Award recognizes innovative research that facilitates a better understanding of the diagnosis, recognition and\/or treatment of ADHD and related disorders. APSARD is solely responsible for the management, decision making and oversight of this award. The 2021 recipients of the award, independently selected by the APSARD Program Committee, are:<\/p>\r\n\r\n\r\n\r\n